Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Depreciation and Depletion: 2024-2025

Historic Depreciation and Depletion for Anika Therapeutics (ANIK) over the last 2 years, with Sep 2025 value amounting to $1.4 million.

  • Anika Therapeutics' Depreciation and Depletion rose 7.69% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year change of. This contributed to the annual value of $5.0 million for FY2024, which is 2.04% up from last year.
  • Anika Therapeutics' Depreciation and Depletion amounted to $1.4 million in Q3 2025, which was up 7.69% from $1.3 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Depreciation and Depletion ranged from a high of $1.4 million in Q3 2025 and a low of $1.2 million during Q1 2024.
  • Moreover, its 2-year median value for Depreciation and Depletion was $1.2 million (2025), whereas its average is $1.3 million.
  • Data for Anika Therapeutics' Depreciation and Depletion shows a peak YoY increased of 8.33% (in 2025) over the last 5 years.
  • Over the past 2 years, Anika Therapeutics' Depreciation and Depletion (Quarterly) stood at $1.2 million in 2024, then grew by 7.69% to $1.4 million in 2025.
  • Its Depreciation and Depletion was $1.4 million in Q3 2025, compared to $1.3 million in Q2 2025 and $1.2 million in Q1 2025.